Why Cytokinetics Stock Was a Nearly 5% Winner Today [Yahoo! Finance]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Yahoo! Finance
style, as its stock price outperformed many other titles by rising nearly 5% on Friday. News of a fresh licensing deal in a key market abroad was the catalyst for the increase, which well exceeded the slightly over 1% gain of the S&P 500 index. A beneficial transfer That morning, Cytokinetics announced that Sanofi has acquired the Greater China development and commercialization rights to aficamten from Chinese healthcare company Corxel. This is a drug targeting heart disease hypertrophic cardiomyopathy (HCM) that was developed by Cytokinetics. Details of the deal, including its price, were not disclosed. Cytokinetics originally sold those rights to Corxel in 2020. The American biotech remains eligible to earn as much as $150 million in development and commercial milestone payments from the new rights holder. Additionally, it can reap royalties on future sales of the drug in Greater China. Cytokinetics said these payments range from the low-to-high-teen percentages of sales. As
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswire
- Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic CardiomyopathyGlobeNewswire
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.MarketBeat
- Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater ChinaGlobeNewswire
CYTK
Earnings
- 11/6/24 - Miss
CYTK
Sec Filings
- 12/16/24 - Form 4
- 12/16/24 - Form 8-K
- 12/16/24 - Form 144
- CYTK's page on the SEC website